Tarsus Pharmaceuticals, Inc. (TARS) Thursday announced positive results from the Phase 2a Carpo trial evaluating TP-05 or lotilaner, an investigational oral therapeutic for the prevention of Lyme disease. TP-05 is an oral systemic formulation of lotilaner, an anti-parasitic agent.
The randomized, double-blind, placebo-controlled trial showed the ability of TP-05 to kill ticks with a single treatment evaluated compared to placebo.
In the pre-market, shares are at $33.00, up 9.53 percent from the previous close of $30.42 on a volume of 455,301.
The company said both the high and low doses of TP-05 demonstrated a statistically significant benefit in killing ticks compared to placebo. Specifically, after the Day 1 tick challenge, mean tick mortality was 97 percent compared to only 5 percent for placebo. At the 30-day challenge, mean tick mortality at 24 hours after placement was 89 percent, compared to only 9 percent for placebo.
Lyme disease is the most common vector-borne disease in the United States, transmitted to humans by Borrelia burgdorferi infection following the bite of a tick vector.
For comments and feedback: editorial@rttnews.com